High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer

Chia Lun Chang, Kevin Sheng Po Yuan, Szu Yuan Wu

研究成果: 雜誌貢獻文章

12 引文 (Scopus)

摘要

Background: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group 2, comprising those receiving high-dose concurrent CRT (n = 5644). Results: Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) for overall mortality was 0.83 (0.78-0.89; P < .001) in patients with oral cavity HNSCC undergoing high-dose concurrent CRT and 0.82 (0.77-0.94; P < .001) in patients with nonoral cavity HNSCC receiving high-dose concurrent CRT. Conclusion: High-dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.
原文英語
期刊Head and Neck
DOIs
出版狀態接受/付印 - 2017

指紋

Squamous Cell Neoplasms
Chemoradiotherapy
Head and Neck Neoplasms
Cisplatin
Radiotherapy
Head
Mouth Neoplasms
Mouth
Comorbidity
Smoking
Regression Analysis
Confidence Intervals
Survival
Mortality
Carcinoma, squamous cell of head and neck
Incidence

ASJC Scopus subject areas

  • Otorhinolaryngology

引用此文

@article{3277085c16de4022b10929c76e29186f,
title = "High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer",
abstract = "Background: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group 2, comprising those receiving high-dose concurrent CRT (n = 5644). Results: Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95{\%} confidence interval [CI]) for overall mortality was 0.83 (0.78-0.89; P < .001) in patients with oral cavity HNSCC undergoing high-dose concurrent CRT and 0.82 (0.77-0.94; P < .001) in patients with nonoral cavity HNSCC receiving high-dose concurrent CRT. Conclusion: High-dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.",
keywords = "Concurrent chemoradiotherapy (CRT), Head and neck cancer, High dose, Low dose, Prognostic factors",
author = "Chang, {Chia Lun} and Yuan, {Kevin Sheng Po} and Wu, {Szu Yuan}",
year = "2017",
doi = "10.1002/hed.24763",
language = "English",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer

AU - Chang, Chia Lun

AU - Yuan, Kevin Sheng Po

AU - Wu, Szu Yuan

PY - 2017

Y1 - 2017

N2 - Background: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group 2, comprising those receiving high-dose concurrent CRT (n = 5644). Results: Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) for overall mortality was 0.83 (0.78-0.89; P < .001) in patients with oral cavity HNSCC undergoing high-dose concurrent CRT and 0.82 (0.77-0.94; P < .001) in patients with nonoral cavity HNSCC receiving high-dose concurrent CRT. Conclusion: High-dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.

AB - Background: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group 2, comprising those receiving high-dose concurrent CRT (n = 5644). Results: Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) for overall mortality was 0.83 (0.78-0.89; P < .001) in patients with oral cavity HNSCC undergoing high-dose concurrent CRT and 0.82 (0.77-0.94; P < .001) in patients with nonoral cavity HNSCC receiving high-dose concurrent CRT. Conclusion: High-dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.

KW - Concurrent chemoradiotherapy (CRT)

KW - Head and neck cancer

KW - High dose

KW - Low dose

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=85017169938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017169938&partnerID=8YFLogxK

U2 - 10.1002/hed.24763

DO - 10.1002/hed.24763

M3 - Article

C2 - 28370614

AN - SCOPUS:85017169938

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -